PHS: Perform Humeral System Study

Sponsor
Stryker Trauma GmbH (Industry)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05067543
Collaborator
(none)
200
2
146.6
100
0.7

Study Details

Study Description

Brief Summary

The purpose of this study is to collect data needed to satisfy the European Union (EU) Medical Device Regulation (MDR) clinical post-market surveillance (PMS) and reporting requirements, and to support future regulatory submissions and peer-reviewed publications on device performance and safety.

Condition or Disease Intervention/Treatment Phase
  • Device: Tornier Perform Humeral - Stem

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Perform Humeral System Study
Actual Study Start Date :
Sep 12, 2021
Anticipated Primary Completion Date :
Jun 30, 2033
Anticipated Study Completion Date :
Dec 1, 2033

Arms and Interventions

Arm Intervention/Treatment
Tornier Perform Humeral System - Stem

Partial or total shoulder arthroplasty using the Tornier Perform Humeral Stem.

Device: Tornier Perform Humeral - Stem
The PERFORM Humeral System - Stem is a non-constrained prosthesis intended for the total or partial replacement of the glenohumeral articulation.

Outcome Measures

Primary Outcome Measures

  1. Change from Baseline to last follow-up visit in ASES scores [Baseline through Follow-Up visits through 24 months Post-Op]

    ASES Score = American Shoulder and Elbow Surgeons Score, 11 items with total score reported out of 100 measuring pain and activity of patient's evaluated shoulder where lower scores indicate more pain and less function

Secondary Outcome Measures

  1. Change from Baseline to last follow-up visit in Constant Murley scores [Baseline through Follow-Up visits through 10 years Post-Op]

    Combination of physician-completed and patient-reported portions to assess functional state of shoulder including range of motion; total score reported out of 100 measuring where lower scores indicate less function of the evaluated shoulder

  2. Change from Baseline to last follow-up visit in SANE scores [Baseline through Follow-Up visits through 10 years Post-Op]

    SANE = Single Assessment Numeric Evaluation; 1 item assessment of shoulder rating 0% to 100%

  3. Change from Baseline to last follow-up visit in Subject Satisfaction scores [Baseline through Follow-Up visits through 10 years Post-Op]

    Single, subjective question measuring patient satisfaction; assessed by improved, worsened, or no change in satisfaction

  4. Change from Baseline to last follow-up visit in EQ-5D scores [Baseline through Follow-Up visits through 10 years Post-Op]

    The EuroQol Five Dimensions Questionnaire (EQ-5D) questionnaire is a standardized instrument for use as a measure of quality of life. It is cognitively simple, takes only a few minutes to complete, and provides a simple descriptive profile as well as a single index value for quality of life that can be used in the clinical and economic evaluation of health care. The EQ-5D consists of a descriptive system which comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression), and a visual analog scale which measures the respondent's self-rated health on a 0-100 scale.

  5. Number of device associated and procedure associated adverse events. [Baseline through Follow-Up visits through 10 years Post-Op]

  6. Rates of revision surgeries. [Baseline through Follow-Up visits through 10 years Post-Op]

  7. Evaluation of radiological imaging of the affected shoulder [Baseline through Follow-Up visits through 10 years Post-Op]

    Images will be analyzed for bone characteristics (baseline and post-op) and device migration, component breakage, and radiolucency (post-op visits only).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • 18 years or older at the time of the informed consent or non-opposition (when applicable).

  • Informed and willing to sign an informed consent form approved by IRB or EC (when applicable).

  • Willing and able to comply with the requirements of the study protocol.

  • Considered a candidate for shoulder arthroplasty using a study device.

  • Meets indications for use requirements or other local, regional, or geographic specific regulatory requirements

Exclusion Criteria:
  • Not able to comply with the study procedures based on the judgment of the assessor (e.g. cannot comprehend study questions, inability to keep scheduled assessment times)

  • Patient belongs to a vulnerable group of patients, including minor patients, those unable to decide for themselves to participate or needing a Legally Authorized Representative (LAR), or others who could be subject to coercion (patients who may not be acting on their own initiative) (referred as "vulnerable subject" in the section 3.44 of the ISO 14155 norm).

  • Active local or systemic infection, sepsis, or osteomyelitis

  • Poor bone quality, where there could be considerable migration of the prothesis and/or a chance of fracture of the humerus or glenoid

  • Significant injury to the brachial plexus

  • Inadequate bone stock in the proximal humerus or glenoid fossa for supporting the components

  • Neuromuscular disease (e.g., joint neuropathy)

  • Patient with known allergy to one of the product materials

  • Metabolic disorders which may impair bone formation

  • Patient pregnancy

  • Planned for two-stage surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Washington University Saint Louis Missouri United States 63110
2 Orthopedic Institute Sioux Falls South Dakota United States 57105

Sponsors and Collaborators

  • Stryker Trauma GmbH

Investigators

  • Study Director: Rebecca Gibson, Stryker Trauma

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Stryker Trauma GmbH
ClinicalTrials.gov Identifier:
NCT05067543
Other Study ID Numbers:
  • 20D-W-PHS-RM
First Posted:
Oct 5, 2021
Last Update Posted:
Jan 10, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 10, 2022